Disclosures for "Vitamin E (Alpha-tocopherol) Central Nervous System (CNS) Effects [Increasing Ramified Microglia; Decreasing Astrocytosis; Decreasing Oxidative Stress Biomarkers; Slowing Amyotrophic Lateral Sclerosis (ALS) Progression from Early to Advanced Disease] and Respiratory System Effects [Decreasing Vital Capacity Loss with Age by Increasing Alpha-tocopherol and Decreasing Gamma-tocopherol; Improving Resistance to Respiratory Bacterial Infections] Require Proper Dose / Dose Exposure Time and Outcome Measures for Future Clinical Trials"
-
Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ITF Pharma. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Cytokinetics. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Muscular Dystrophy Association. The institution of Dr. Brooks has received research support from Orion. Dr. Brooks has received research support from Alexion. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. The institution of Dr. Brooks has received research support from Biohaven. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with American Academy of Neurology that is relevant to AAN interests or activities.